Brazilian Journal of Anesthesiology
https://bjan-sba.org/article/doi/10.1016/j.bjane.2015.08.003
Brazilian Journal of Anesthesiology
Scientific Article

Comparison of the effects of sugammadex and neostigmine on postoperative nausea and vomiting

Comparação dos efeitos de sugamadex e neostigmina em náusea e vômito no pós-operatório

Özgür Yağ; an; Nilay Taş; ; Tuğ; çe Mutlu; Volkan Hancı;

http://dx.doi.org/10.1016/j.bjane.2015.08.003 Braz J Anesthesiol, vol.67, n2, p.147-152, 2017
PDF English
PDF Português
Downloads: 0
Views: 737

Abstract

Abstract Background and objectives: The aim of our study is to compare the effects of sugammadex and neostigmine, used for neuromuscular blockage antagonism, on postoperative nausea and vomiting (PONV). Methods: Our study was completed with 98 ASA I-II risk patients undergoing endotracheal intubation under general anesthesia. At the end of the surgery patients were randomly divided into two groups given 2 mg kg-1 sugammadex (Group S) or 50 µg kg-1 neostigmine plus 0.2 mg kg-1 atropine (Group N). Monitoring and recording times were set as 1 hour postoperative and from 1-6, 6-12, and 12-24 hours. The anti-emetic amounts administered were recorded. Results: In the first hour postoperative 13 patients in Group N (27%) and 4 in Group S (8%) were observed to have nausea and/or vomiting and the difference was statistically significant (p = 0.0016). During the 24 hours of monitoring there was no significant difference in the incidence and severity of PONV (p > 0.05), however the number of patients given ondansetron for PONV treatment in Group N was statistically significantly higher than the number in Group S (16 in Group N, 6 in Group S, p < 0.011). Conclusions: At the end of our study comparing neostigmine with sugammadex for neuromuscular blockage antagonism, we found use of sugammadex had lower incidence of PONV in the postoperative 1st hour and less anti-emetic use in 24 hours of monitoring.

Keywords

Sugammadex, Neostigmine, Postoperative, Nausea, Vomiting

Resumo

Resumo Justificativa e objetivos: O objetivo de nosso estudo foi comparar os efeitos de sugamadex e neostigmina, usados para o antagonismo do bloqueio neuromuscular em náusea e vômito no pós-operatório (NVPO). Métodos: O estudo foi concluído com 98 pacientes de risco ASA I-II, submetidos à intubação traqueal sob anestesia geral. Ao final da cirurgia, os pacientes foram aleatoriamente divididos em dois grupos que receberam 2 mg kg-1 de sugamadex (Grupo A) ou 50 µg kg-1 de neostigmina mais 0,2 mg kg-1 de atropina (Grupo N). Os tempos de monitoração e registro foram definidos como uma hora de pós-operatório e de 1-6, 6-12 e 12-24 horas. As quantidades administradas de antieméticos foram registradas. Resultados: Na primeira hora de pós-operatório, 13 pacientes do Grupo N (27%) e 4 do Grupo S (8%) apresentaram náusea e/ou vômito e a diferença foi estatisticamente significativa (p = 0,0016). Não houve diferença significativa na incidência e gravidade de NVPO (p > 0,05) durante as 24 horas de monitoração, porém o número de pacientes que receberam ondansetron para o tratamento de NVPO no Grupo N foi estatística e significativamente maior que o número de pacientes no Grupo S (16 e 6, respectivamente, p < 0,011). Conclusões: Ao final do estudo quando comparamos neostigmina com sugamadex para o antagonismo do bloqueio neuromuscular descobrimos que sugamadex apresentou menor incidência de NVPO na primeira hora de pós-operatório e consumo menor de antiemético em 24 horas de monitoração.

Palavras-chave

Sugamadex, Neostigmina, Pós-operatório, Náusea, Vômito

References

Kapur PA. The big "little problem". Anesth Analg. 1991;73:243-5.

Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology. 1992;77:162-84.

Kenny GN. Risk factors for postoperative nausea and vomiting. Anaesthesia. 1994;49:6-10.

Apfel CC, Greim CA, Haubitz I. A risk score to predict the probability of postoperative vomiting in adults. Acta Anaesthesiol Scand. 1998;42:495-501.

Apfel CC, Greim CA, Haubitz I. The discriminating power of a risk score for postoperative vomiting in adults undergoing various types of surgery. Acta Anaesthesiol Scand. 1998;42:502-9.

Figueredo E, Canosa L. Prophylactic ondansetron for postoperative emesis. Meta-analysis of its effectiveness in patients with previous history of postoperative nausea and vomiting. Acta Anaesthesiol Scand. 1999;43:637-44.

Tramer MR, Fuchs-Buder T. Omitting reversal of neuromuscular blockade: effect on postoperative nausea and vomiting and risk of residual paralysis: a systemic review. Br J Anaesth. 1999;82:379-86.

Jokela R, Koivuranta M. Tropisetron or droperidol in the prevention of postoperative nausea and vomiting. A comparative, randomised, double-blind study in women undergoing laparoscopic cholecystectomy. Acta Anaesthesiol Scand. 1999;43:645-50.

de Boer HD, van Egmond J, van de Pol F. Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: reversal of neuromuscular block in anaesthetized Rhesus monkeys. Br J Anaesth. 2006;96:201-6.

Gijsenbergh F, Ramael S, Houwing N. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology. 2005;103:695-703.

Sorgenfrei IF, Norrild K, Larsen PB. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006;104:667-74.

Mirakhur RK. Sugammadex in clinical practice. Anaesthesia. 2009;64:45-54.

Koyuncu O, Turhanoglu S. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: a randomized, blinded trial. J Clin Anesth. 2015;27:51-6.

Apfel CC, Laara E, Koivuranta M. A simplified risk score for predicting postoperative nausea and vomiting. Anesthesiology. 1999;91:693-700.

Gan TJ, Meyer TA, Apfel CC. Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2007;105:1615-28.

Løvstad RZ, Thagaard KS, Berner NS. Neostigmine 50 microg kg(-1) with glycopyrrolate increases postoperative nausea in women after laparoscopic gynaecological surgery. Acta Anaesthesiol Scand. 2001;45:495-500.

King MJ, Milazkiewicz R, Carli F, Deacock AR. Influence of neostigmine on postoperative vomiting. Br J Anaesth. 1988;61:403-6.

Ding Y, Fredman B, White PF. Use of mivacurium during laparoscopic surgery: effect of reversal drugs on postoperative recovery. Anesth Analg. 1994;78:450-4.

Ho KM, Ismail H, Lee KC. Use of intrathecal neostigmine as an adjunct to other spinal medications in perioperative and peripartum analgesia: a meta-analysis. Anaesth Intensive Care. 2005;33:41-53.

Cheng CR, Sessler DI, Apfel CC. Does neostigmine administration produce a clinically important increase in postoperative nausea and vomiting?. Anesth Analg. 2005;101:1349-55.

Hovorka J, Korttila K, Nelskylä K. Reversal of neuromuscular blockade with neostigmine has no effect on the incidence or severity of postoperative nausea and vomiting. Anesth Analg. 1997;85:1359-61.

Nelskylä K, Yli-Hankala A, Soikkeli A. Neostigmine with glycopyrrolate does not increase the incidence or severity of postoperative nausea and vomiting in outpatients undergoing gynaecological laparoscopy. Br J Anaesth. 1998;81:757-60.

Ledowski T, Falke L, Johnston F. Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade: sugammadex, neostigmine or no reversal. Eur J Anaesthesiol. 2014;31:423-9.

5dcd911d0e88256026bf58f1 rba Articles
Links & Downloads
2352-2291 (Electronic) 0104-0014 (Printed)
Braz J Anesthesiol ©2024 All rights reserved.

Braz J Anesthesiol

Share this page
Page Sections